— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — —...
Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well...
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with...
IRVINE, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet...
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”...
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Updates on Recent Transaction and Business will be ProvidedOXNARD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp....
MELBOURNE, Australia, July 28, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader...
MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on...
BOSTON, July 28, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled...
Seasoned Biopharma Executives Bring Significant Clinical Development and Commercial Expertise Michael Brubaker, Ph.D., Xequel Bio, Chief Scientific Officer “The addition...
Building on a Successful Pilot Study, the Two Companies are Further Validating the Link Between Gut Health and HappinessSAN DIEGO...
Brings differentiated miniaturization technology, scientific and engineering expertise, and enhanced ease-of-use capabilities to SomaLogic’s platform while expanding footprint to San...
LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies...
Philogen announces enrolment of 214 patients in the Nidlegy™ Phase III European clinical trial for the treatment of locally advanced...
SILICON VALLEY, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company committed to advancing precision medicine...
SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...
-- European Commission decision anticipated in fourth quarter of 2022 -- BOSTON, July 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals,...
HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapiesTOKYO,...